Research for correlation between ESA resistance and serum hepcidin concentration

Torii Pharmaceutical Co., Ltd.0 个研究点目标入组 60 人开始时间: 2023年9月8日最近更新: 2025年5月9日

试验速览

暂无简介。

•(1) Patients aged 18 years or older at the time of informed consent
•(2) Patients receiving hemodialysis (including hemodiafiltration) 3 times a week for at least 12 weeks prior to informed consent
•(3) Patients receiving ESA treatment for at least 8 weeks prior to informed consent, and whose latest ESA treatment interval is within 4 weeks
•(4) Patients who have been administered the same type of ESA for at least 8 weeks prior to informed consent, and the administration interval and dose of the last two times are same (Epogin, Espo, and Epoetin Alfa Biosimilar are considered the same type of ESA)
•(5) Patients who are assessed to have no health problems for the participation in this study by principal investigator or co-investigators

•(1) Patients with severe complications such as cerebral, hepatic, renal, cardiac, pulmonary, gastrointestinal, hematological, endocrine, metabolic or psychiatric disease
•(2) Those who have participated in other clinical trials involving medical devices or clinical research involving interventions within 12 weeks prior to this study
•(3) Patients judged to be unsuitable as research subjects by principal investigator or co-investigators

Correlation between ERI and serum hepcidin concentration

发起方